Bloomberg Special Reports: Corporate Tax Inversions ^ a b "SEC Form 10-K: Horion Pharma public limited company".^ "Amgen to buy Horizon Therapeutics in $26.4 billion deal".^ "Horizon Therapeutics Public Ltd Co 2021 Annual Report (Form 10-K)".^ "US Biopharma Firm Amgen To Acquire Horizon Therapeutics For $28 Bn".Outside the United States, Rayos is also known as Lodotra. The company's lead product base includes Krystexxa, Duexis and Rayos. Horizon's portfolio includes Tepezza ( teprotumumab), Krystexxa ( pegloticase), Actimmune ( interferon gamma), Duexis (ibuprofen + famotidine), Pennsaid (diclofenac, 2% topical), Rayos/Lodotra ( prednisone), Vimovo ( naproxen/ esomeprazole magnesium), Buphenyl ( sodium phenylbutyrate), Procysbi ( cysteamine bitartrate), and Ravicti ( glycerol phenylbutyrate). Horizon's drug portfolio is focused on treatments for thyroid eye disease (TED), gout, rare diseases, and inflammatory diseases. It is also expanding its development and manufacturing facility in Waterford (Ireland) for the production of rare disease biologics and drugs still in development.
In early 2022, the company signed a lease on a large research and development facility in Rockville, Maryland. In July 2015, the Wall Street Journal noted that Horizon were using their lower Irish corporate tax rate to acquire further U.S.–based life sciences firms (i.e. While Horizon's main operations and sales remained in the U.S., Horizon moved their "legal" headquarters to Ireland to avoid U.S. In March 2014, the company executed a corporate tax inversion to Ireland by acquiring Irish–based Vidara Therapeutics International for $660 million. In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). The program is planned to promote communications between physicians and patients about NSAIDs and gastrointestinal ulcers. The company has cooperated with American Gastroenterological Association (AGA) Institute to launch a program named "Connect to Protect" which aims to help physicians and patients better understand non-steroidal anti-inflammatory drug (NSAID) risks.
Horizon Therapeutics sales by region (2017) Region In May 2023, the Federal Trade Commission said it would sue to block the deal in an attempt to control drug prices. The company was reportedly the center of a bidding war between Amgen, Johnson & Johnson and Sanofi. In December 2022, the company announced it would be acquired by Amgen for $27.8 billion ($116.50 in cash for each Horizon share, a 20% premium). In February 2021, the business announced it would acquire Viela Bio Inc for around $3 billion ($53 per share). Horizon believed it could reach $1 billion peak sales in the US alone. In January 2020 – after showing very strong PhIII data – it was approved for the treatment of thyroid eye disease (TED), a rare vision-threatening disease that previously had no FDA-approved treatment options. On May 2, 2019, shareholders of the company approved the change of the company's name from Horizon Pharma plc to Horizon Therapeutics plc. In 2017, Horizon announced its intention to acquire River Vision Development Corp for $145 million and to continue the development of teprotumumab. In September 2016, the company announced the acquisition of Raptor Pharmaceutical for $800 million, adding Procysbi and Quinsair to its rare drug portfolio. In December, the company acquired Crealta Holdings for $510 million. In March 2015, the company acquired Hyperion Therapeutics for $1.1 billion, increasing Horizon's orphan disease drug portfolio. In October 2014, the company acquired the US sales and marketing rights to the osteoarthritis drug Pennsaid from Nuvo Research for $45 million. In 2014, Horizon executed a tax inversion to move its legal headquarters to Ireland to avail itself of Ireland's low tax rates and beneficial corporate tax system.
Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Horizon Therapeutics is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases.
0 kommentar(er)
